Merck KGaA, Darmstadt, Germany and Bio-Techne Corp., a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, ...
The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said. Merck KGaA has agreed to buy Bio-Techne for $11.3 billion ...
Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, the companies said today, in a deal designed to position the buyer as more of a leader across the life ...
11don MSN
Bio-Techne is today’s top S&P 500 stock. Germany’s Merck is paying a 24% premium for the company
Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.
Medical Device Network on MSN
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion
The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.
Merck KGaA agreed to buy Bio-Techne Corporation for about $11.3 billion to bolster its life-science business, marking the ...
Germany's Merck KGaA is poised to increase the size of its life sciences business, which provides tools for research, drug discovery, and manufacturing, with an $11.3 billion deal to acquire US rival ...
German pharmaceutical company Merck KGaA to purchase Bio-Techne in $11.3 billion transaction Acquisition price set at $73 per share, representing a 24% premium over Wednesday’s close Bio-Techne shares ...
Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Bio-Techne (TECH) rose 4% on a report that activist investor Ananym Capital Management has accumulated a stake in the maker of life-sciences tools and wants the company to pursue a strategic review, ...
Activist investor Ananym Capital Management has built a stake in Bio-Techne Corp. and is pushing the board to conduct a strategic review that would include a potential sale. Ananym said in a letter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results